Sepracor (Marlborough, Massachusetts) reported that clinical data for XOPENEX HFA (levalbuterol tartrate) Inhalation Aerosol will be presented at the American College of Allergy, Asthma and Immunology (ACAAI; Arlington Heights, Illinois) annual meeting in Philadelphia this weekend.
The poster entitled, “Cumulative Dose Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Patients with Asthma” will be displayed in Exhibit Hall D of the Pennsylvania Convention Center.
XOPENEX HFA is a hydrofluoroalkane (HFA) metered-dose inhaler (MDI), a portable, hand-held device consisting of a pressurized canister containing medication and a mouthpiece through which the medication is inhaled. XOPENEX HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children 4 and older with reversible obstructive airway disease.
Sepracor develops pharmaceutical products focused on respiratory and central nervous system disorders.